Enhancing Motor Task Training by Action Observation Watching Others Perform the Task

Enhancing Motor Memory Encoding by Action Observation

This study will determine how the brain learns a new motor task when the subject practices the task and watches others perform it (action observation) at the same time.

Healthy normal volunteers between 18 and 55 years of age may be eligible for this study. Candidates are screened with a medical history, general and neurological exam, and a brain MRI if one has not been done within 12 months of entering the study. Participants undergo one or both of the following experiments:

  1. Effect of Transcranial Magnetic Stimulation on Motor Training and Action Observation

    Subjects participate in at least 12 4-hour test sessions, separated by at least 1 day. Each session includes the following:

    • Functional MRI (fMRI): MRI scanning uses a magnetic field and radio waves to produce images of the brain. For fMRI, the subject performs tasks during the scan to allow researchers to see brain changes that occur during performance of the activity.
    • Transcranial magnetic stimulation (TMS): For this test, a wire coil is held on the scalp. A brief electrical current passes through the coil to stimulate the brain. The stimulation may cause a twitch in muscles of the face, arm, or leg, and the subject may hear a click and feel a pulling sensation on the skin under the coil. During the stimulation, the subject is asked to: 1) perform the training task (make brisk thumb movements); 2) watch a video showing the hand of another person performing the same task; and 3) perform the task and watch the video at the same time, synchronizing his or her movements with those observed in the video.
    • Surface electromyography: Electrodes are filled with a conductive gel and taped to the skin over a hand muscle to measure the electrical activity of the muscle.
    • Behavioral measurements: Evaluation of learned movement tasks.
    • Questionnaires to test attention, fatigue and mood before, during and after each test session.
  2. Effect of Pharmacological Agents on Motor Training and Action Observation

Subjects participate in no more than 12 5-hour test sessions, separated by at least 2 days. In the course of the 12 sessions, subjects receive each of three medications - dextromethorphan, scopolamine and rivastigmine - three times and a placebo (pill with no active ingredient) three times. During each session, subjects have TMS measurements, behavioral measurements and electromyography as described in experiment 1.

Study Overview

Status

Completed

Conditions

Detailed Description

Motor training (MT) elicits formation of motor memories in the human primary motor cortex. Observing another individual perform motor training (Action Observation, AO) also results in formation of motor memories in M1. AO enhances motor training effects (MT+AO) on the formation of motor memories. Possible underlying mechanisms include long-term potentiation (LTP), a process influenced by N-methyl-D-aspartate (NMDA) receptor activation, gamma-aminobutyric acid (GABA), norepinephrine (NE), dopamine and acetylcholine (Ach), taking place at the confluence of inputs from PMv over the primary motor cortex (M1).

The purpose of this protocol is to gain insight into the mechanisms underlying motor memory formation by MT+AO. We plan to perform two different types of experiments: In experiment 1, we will modulate activity in PMv using TMS to investigate the role of this cortical area on motor memory formation induced by MT+AO. In experiment 2, we will test the effects of single doses of (a) the NMDA receptor antagonist dextromethorphan, (b) the muscarinic receptor antagonist scopolamine, both known to disrupt LTP, and (c) the cholinesterase inhibitor rivastigmine, which enhances LTP.

The primary outcome measure of motor memory formation will be the percentage of TMS-evoked movements that fall within the training target zone (TTZ) before and after MT+AO. The secondary outcome measure will be the percentage of TMS-evoked movements that fall within TTZ before and after MT alone and AO alone.

Expected results are (1) upregulation of activity in PMv using 0.1 Hz TMS will enhance motor memory formation induced by MT+AO more than sham TMS and downregulation of PMv using 0.9 Hz TMS and (2) dextromethorphan and scopolamine will decrease but rivastigmine will increase motor memory formation induced by MT+AO with placebo. This study may provide useful information on the mechanisms underlying the beneficial effects of action observation on neuroplasticity.

Study Type

Observational

Enrollment

40

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Maryland
      • Bethesda, Maryland, United States, 20892
        • National Institutes of Health Clinical Center, 9000 Rockville Pike

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 55 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

  • INCLUSION CRITERIA:

    1. Age between 18-55 years
    2. Able to perform tasks required by the study
    3. Willing and able to give consent
    4. Possibility to obtain TMS-evoked thumb movements in a consistent direction at baseline

EXCLUSION CRITERIA:

Subjects are not eligible for this experiment if they:

  1. Are unable to perform the tasks
  2. Have history of severe alcohol or drug abuse, psychiatric illness like severe depression and poor motivational capacity
  3. Have problems with movement of the hands
  4. Are receiving drugs acting primarily on the central nervous system
  5. Are pregnant
  6. Have medical or technical contraindications to MRI procedures or devices producing artifacts that impair MRI signal (e.g., dental braces, pacemakers, implanted medication pumps, cochlear devices, neural stimulators, metal in the cranium, surgical clips, and other metal/magnetic implants, claustrophobia)
  7. Have had an allergic reaction to scopolamine. Have glaucoma, severe liver disease, kidney disease, an enlarged prostrate gland or a blocked digestive tube
  8. Have had an allergic reaction to dextromethorphan
  9. Are using a MAO inhibitor (such as Parnate [registered trademark], Nardil [registered trademark], or Marplan [registered trademark] or if you have used one of these drugs in the past 2 weeks
  10. Have asthma
  11. Are taking pain or arthritis medicine (sometimes called NSAIDs) such as aspirin, ibuprofen, or naproxen on a regular basis

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 18, 2006

Study Completion

July 18, 2008

Study Registration Dates

First Submitted

October 26, 2006

First Submitted That Met QC Criteria

October 26, 2006

First Posted (Estimate)

October 27, 2006

Study Record Updates

Last Update Posted (Actual)

July 2, 2017

Last Update Submitted That Met QC Criteria

June 30, 2017

Last Verified

July 18, 2008

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe